Allogene Therapeutics, Inc. Net Fee Amt
Allogene Therapeutics, Inc. (ALLO) had Net Fee Amt of $69.05 thousand as of 2026-08-06, per its S-3 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-06: Net Fee Amt $69.05K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-06 | $69.05K S-3 · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |